Biota Pharmaceuticals Inc

Type: Company
Name: Biota Pharmaceuticals Inc
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play" Search BioPortfolio:Loading ... [Published BioPortfolio - Oct 20 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

10-K - Biota Pharmaceuticals, Inc. (0000072444) (Filer)

Document Format FilesSeq Description Document Type Size 1 FORM 10-K bota20140630_10k.htm 10-K 2179902 2 EXHIBIT 21.1 ex21-1.htm EX-21 3458 3 EXHIBIT 23.1 ex23-1.htm EX-23 3203 4 EXHIBIT 23.1A ex23-1a.htm EX-23 3215 5 EXHIBIT 31.1 ex31-1.htm EX-31 11167 ... [Published SEC - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Biota Pharma reports fiscal year results

News EditorBiota Pharmaceuticals (BOTA -0.8%) financial results:Fiscal Q4: Revenues: $8.5M (-8.6%); Operating Expenses: $19.0M (+21.0%); Operating Loss: ($10.5M) (-64.1%); Net Loss: ($10.2M) (-56.9%); Loss Per Share: ($0.29) (-26.1%); Quick Assets: $81.7M ... [Published Seeking Alpha - Sep 30 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

MannKind and Sanofi Complete Afrezza Collaboration Deal

Below is a look at some of the headlines for companies that made news in the healthcare sector on September 26, 2014.MannKind Corporation ($MNKD) has been in search of a suitable partner ever since the FDA cleared Afrezza inhalation powder for the improvement ... [Published BioMedReports - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

BioNews [9.26.14]

Top News HeadlineCompanyType Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration Pharmacyclics & ServierEnded Collaboration This Switch Could Make Gilead Sciences, Inc. Stock Billions Gilead Sciences, Inc.Block ... [Published eClinical Trends - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 5 reports

Biota Pharmaceuticals announces changes to management and board of directors

12:00pm BSTBiota Pharmaceuticals Inc:Appoints Joseph M. Patti as the company's President and Chief Executive Officer and as a director.Says Patti is replacing Russell H. Plumb, the company's current President and Chief Executive Officer, who will assume ... [Published Reuters UK - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

3 Biotech Stocks Under $10 to Trade for Breakouts

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers. Must Read: Sell These 5 Toxic Stocks Before the Next DropStocks that are making large moves ... [Published The Street Latest - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 3 reports

Biota Pharmaceuticals Reports Fourth Quarter and -2-

The Company plans to initiate a randomized, double-blind, placebo-controlled dose-ranging Phase 2 trial in moderate and severe asthmatic patients at risk of loss of asthma control due to presumptive human rhinovirus (HRV) infection in the first quarter ... [Published Scottrade - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Earnings Scheduled For September 26, 2014

Finish Line (NASDAQ: FINL) is projected to report its Q2 earnings at $0.60 per share on revenue of $478.07 million.BlackBerry (NASDAQ: BBRY) is estimated to report a Q2 loss at $0.16 per share on revenue of $949.64 million.Biota Pharmaceuticals (NASDAQ: ... [Published Benzinga.com - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 1 reports

Bronchopulmonary Dysplasia and Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2014

DALLAS , Sept. 24, 2014 /PRNewswire-iReach/ -- These reports provide comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia and Respiratory Syncytial Virus (RSV) Infections. These reports provides comparative analysis ... [Published Myrtle Beach Sun News - Sep 24 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Biota Pharma announces positive results from phase 2 IGLOO trial of laninamivir octanoate

Biota Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced top-line data from a randomised, double-blind, ... [Published PharmaBiz - Aug 05 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.

SAN DIEGO--(BUSINESS WIRE)--BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc ... [Published Business Wire Professional Services News - Aug 01 2014]

Quotes

...our value creation potential", stated Russell H Plumb, President and Chief Executive Officer of Biota PharmaceuticalsBiota Pharmaceuticals Inc. "Based on the significant progress we have made with our non-influenza antiviral programs over the past several months, we plan to initiate a Phase 2 trial of vapendavir early next year and advance BTA-C585, our RSV fusion inhibitor, through IND-enabling studies and into Phase 1 clinical trials in mid-2015."
...and am excited about our prospects and our pipeline of antivirals focused on the treatment of respiratory viral infections," commented Dr. Patti. "I believe our fiscally responsible operating model, as well as our plans to consider a number of strategic opportunities to complement our pipeline, initiate a Phase 2 trial in the first quarter of 2015 with vapendavir and complete ongoing IND-enabling studies and progress BTA-C585 into the clinic in mid-2015 to treat RSV infections bode well for Biota and its shareholders over the next 12-18 months."
...in the time to alleviate patient-reported influenza symptoms," stated Russell H Plumb, the company's president and chief executive officer, "We expect to complete a full analysis of additional clinical, safety, and pharmacokinetic data forthcoming from this trial over the next several months; however, at this time we do not have any plans to independently advance the development of LANI for the treatment of influenza and intend to evaluate next steps for the LANI programme outside of Japan with our partner, Daiichi Sankyo."

More Content

All (32) | News (17) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (12)
sort by: Date | Relevance
Biota Pharmaceuticals: An Undervalued Long-Term... [Published BioPortfolio - Oct 20 2014]
10-K - Biota Pharmaceuticals, Inc. (0000072444)... [Published SEC - Sep 30 2014]
Biota Pharma reports fiscal year results [Published Seeking Alpha - Sep 30 2014]
MannKind and Sanofi Complete Afrezza Collaborat... [Published BioMedReports - Sep 27 2014]
BioNews [9.26.14] [Published eClinical Trends - Sep 26 2014]
Biota Pharmaceuticals announces changes to mana... [Published Reuters UK - Sep 26 2014]
3 Biotech Stocks Under $10 to Trade for Breakouts [Published The Street Latest - Sep 26 2014]
Biota Pharmaceuticals Inc gives charge outlook,... [Published Reuters - Sep 26 2014]
Biota Posts Wider Loss In Q4; Joseph Patti Repl... [Published RTTNews.com - Sep 26 2014]
Biota Pharmaceuticals (BOTA) Announces Quarterl... [Published American Banking News - Forex - Sep 26 2014]
Biota Pharmaceuticals Announces Changes to Mana... [Published GlobeNewswire: Acquisitions News - Sep 26 2014]
Biota Pharmaceuticals Reports Fourth Quarter an... [Published GlobeNewswire: Acquisitions News - Sep 26 2014]
Biota Pharmaceuticals misses by $0.11, misses o... [Published Seeking Alpha - Sep 26 2014]
Biota Pharmaceuticals Reports Fourth Quarter an... [Published Scottrade - Sep 26 2014]
Biota Pharmaceuticals Reports Fourth Quarter an... [Published Tamar Securities - Sep 26 2014]
Biota Pharmaceuticals Announces Changes to Mana... [Published Reliance Trust - Sep 26 2014]
Earnings Scheduled For September 26, 2014 [Published Benzinga.com - Sep 26 2014]
Bronchopulmonary Dysplasia and Respiratory Sync... [Published Myrtle Beach Sun News - Sep 24 2014]
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Advertising News - Sep 15 2014]
Biota to Present Preclinical Data on RSV Compou... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Biota Pharma announces positive results from ph... [Published PharmaBiz - Aug 05 2014]
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
5 Stocks Under $10 Set to Soar [Published The Street Latest - Jul 11 2014]
Research and Markets: Biota Pharmaceuticals, In... [Published Business Wire Health News - Jun 04 2014]
Biota Announces Restructuring Plan [Published GlobeNewswire: Advertising News - Jun 02 2014]
34% Drop in Biota Pharmaceutical, Inc.'s Stock ... [Published Financial Services - May 12 2014]
Faruqi & Faruqi, LLP Encourages Investors Who S... [Published Financial Services - May 10 2014]
Biota Provides Update on BARDA Contract for Lan... [Published GlobeNewswire: Advertising News - May 08 2014]
Biota Pharmaceuticals Reports Third Quarter 201... [Published GlobeNewswire: Advertising News - May 06 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioNews [9.26.14] [Published eClinical Trends - Sep 26 2014]
Top News HeadlineCompanyType Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration Pharmacyclics & ServierEnded Collaboration This Switch Could Make Gilead Sciences, Inc. Stock Billions Gilead Sciences, Inc.Block ...
BIOTA ALERT: Shareholder Rights Law Firm Johnso... [Published Business Wire Professional Services News - Aug 01 2014]
SAN DIEGO--(BUSINESS WIRE)--BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc ...
Research and Markets: Biota Pharmaceuticals, In... [Published Business Wire Health News - Jun 04 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/965h3w/biota) has announced the addition of the "Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014" company profile to their offering. This report provides ...
1

Press Releases

sort by: Date | Relevance
Biota Pharmaceuticals Announces Changes to Mana... [Published GlobeNewswire: Acquisitions News - Sep 26 2014]
Biota Pharmaceuticals Reports Fourth Quarter an... [Published GlobeNewswire: Acquisitions News - Sep 26 2014]
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Advertising News - Sep 15 2014]
Biota to Present Preclinical Data on RSV Compou... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Biota Reports Top-Line Data From Its Phase 2 "I... [Published GlobeNewswire: Acquisitions News - Aug 01 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.